首页|Associations between Mycobacterium tuberculosis Beijing genotype and drug resistance to four first-line drugs: a survey in China

Associations between Mycobacterium tuberculosis Beijing genotype and drug resistance to four first-line drugs: a survey in China

扫码查看
Investigations on the genetic diversity of Mycobacterium tuberculosis in China have shown that Beijing genotype strains play a dominant role.To study the association between the M.tuberculosis Beijing genotype and the drug-resistance phenotype,1286 M.tuberculosis clinical isolates together with epidemiological and clinical information of patients were collected from the center for tuberculosis (TB) prevention and control or TB hospitals in Beijing municipality and nine provinces or autonomous regions in China.Drug resistance testing was conducted on all the isolates to the four first-line anti-TB drugs (isoniazid,rifampicin,streptomycin,and ethambutol).A total of 585 strains were found to be resistant to at least one of the four anti-TB drugs.The Beijing family strains consisted of 499 (53.20%) drug-sensitive strains and 439 (46.80%) drug-resistant strains,whereas the non-Beijing family strains comprised 202 (58.05%) drug-sensitive strains and 146 (41.95%) drug-resistant strains.No significant difference was observed in prevalence (x2=2.41,P > 0.05) between the drug-resistant and drug-sensitive strains among the Beijing family strains.Analysis of monoresistance,multidrug-resistant TB,and geographic distribution of drug resistance did not find any relationships between the M.tuberculosis Beijing genotype and drug-resistance phenotype in China.Results confirmed that the Beijing genotype,the predominant M.tuberculosis genotype in China,was not associated with drug resistance.

tuberculosisdrug resistancegenotypemolecular biology

Haican Liu、Yuanyuan Zhang、Zhiguang Liu、Jinghua Liu、Yolande Hauck、Jiao Liu、Haiyan Dong、Jie Liu、Xiuqin Zhao、Bing Lu、Yi Jiang、Gilles Vergnaud、Christine Pourcel、Kanglin Wan

展开 >

State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China

University Paris-Sud, Institut de Génétique et Microbiologie, UMR 8621, Orsay, France

Department of Epidemiology and Health Statistics, Public Health of Central South University, Changsha 421001, China

DGA/MRIS-Mission pour la Recherche et l'Innovation Scientifique, Bagneux, France

CNRS, Orsay, France

展开 >

This work was funded by the projects of the National Key Program of Mega Infectious DiseaseThis work was funded by the projects of the National Key Program of Mega Infectious Diseaseproject of the State Key Laboratory for Infectious Disease Prevention and Control

2013ZX10003006-0022013ZX10003002-0012011SKLID-2008

2018

医学前沿
高等教育出版社

医学前沿

CSCDSCI
影响因子:1.362
ISSN:2095-0217
年,卷(期):2018.12(1)
  • 6
  • 23